Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MPN Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Interventions
bezuclastinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced May 22, 2026, 1:30 AM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Phase II, Imetelstat, Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
Interventions
Imetelstat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Myelofibrosis, Essential Thrombocythemia, MPN
Interventions
Peptide-based vaccine, Poly ICLC
Drug
Lead sponsor
Marina Kremyanskaya
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced May 22, 2026, 1:30 AM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Questionnaire Administration, Ropeginterferon Alfa-2B
Procedure · Other · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Myeloproliferative Neoplasm, COVID
Interventions
Not listed
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Other
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Freeze-Dried Black Raspberry Powder
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Hematologic Malignancies, Solid Tumor
Interventions
PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
47
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced May 22, 2026, 1:30 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
155
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
BGB-11417, Azacitidine, Posaconazole
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Myeloproliferative Neoplasm, Unclassifiable
Interventions
Not listed
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced May 22, 2026, 1:30 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
Interventions
Not listed
Lead sponsor
MPN Research Foundation
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Interventions
reparixin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Best Available Therapy
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
Interventions
KT-253
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
11
States / cities
Scottsdale, Arizona • Sacramento, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
Interventions
Sotatercept, Ruxolitinib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Itacitinib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Tempe, Arizona • Orange, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Myeloproliferative Neoplasm, MPN, Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis
Interventions
N-Acetylcysteine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
TAS1553
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Myelomonocytic, Chronic
Interventions
Tipifarnib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Thrombocytosis, Myeloproliferative Neoplasms
Interventions
Anagrelide CR
Drug
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Burbank, California • Encinitas, California • Escondido, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
Interventions
Canakinumab
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions
Pomalidomide 0.5 mg, Placebo, Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced May 22, 2026, 1:30 AM EDT